[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446430":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[68Ga]-Pentixafor","EXPERIMENTAL","An intravenous bolus of 3 -5 mCi \\[68Ga\\]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET\u002FCT device. Any of the following factors may determine if imaging cannot be performed: tolerance\u002Fcompliance in the PET\u002FCT scanner; dose availability; dose quality control; availability of the PET\u002FCT scanner or availability of study personnel. \\[68Ga\\]-Pentixafor uptake dynamics \u002F pharmacokinetics will be evaluated by PET\u002FCT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). \\[68Ga\\]-Pentixafor-PET\u002FCT scan duration will be approximately 1.5 hours. Some patients will have two scans.",[13],"Drug: [68Ga]-Pentixafor",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","An intravenous bolus of 3 -5 mCi of \\[68Ga\\]-Pentixafor will be injected in all participants.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Anton Nosov, MD","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","212-639-8575","nosova@mskcc.org",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":19},"Heiko Schoder, MD","212-639-2079",[33],{"facility":5,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","New York","10065","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-74.00597,40.71427,{"lat":43,"lon":42},[46,47],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":19},{"name":30,"role":26,"phone":31,"phoneExt":19,"email":19},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100446430","early-phase-1-in-human-cxcr4-imaging-of-hematologic-and-solid-tumors-using-68ga-pentixafor-pet-100446430",false,"NCT05093335","In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET","In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET","Inclusion Criteria:\n\nTwenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:\n\n* Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria\n\nor\n\n* Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and\u002For Rosai-Dorfman disease (RDD)\n* MGUS\u002FSMM or MM according to IMWG definitions\n* Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease.\n* Age ≥18\n* Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \\& Guidelines) from assays obtained \\\u003C2 weeks prior to study enrollment\u002Fintervention; or negative urine pregnancy test performed on the day of intervention\n* MSKCC patients\n\nExclusion Criteria:\n\n* Breast-feeding\n* History of renal functional disorders (chronic kidney disease with eGFR\\\u003C30)\n* Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)","ALL","18 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"EARLY_PHASE1","The purpose of this study is to determine the uptake of the imaging agent \\[68Ga\\]-pentixafor with PET\u002FCT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and\u002For Rosai-Dorfman disease (RDD).",[67,68,69,70,71],"Non-Hodgkin Lymphoma","Multiple Myeloma","Histiocytic Neoplasms","Erdheim-Chester Disease","Rosai-Dorfman Disease",[9,73,74,75,76,77,78,79,5],"PET\u002FCT scan","In-human CXCR4 Imaging","21-356","Symptomatic multiple myeloma","pre-cursor myeloma","MGUS","SMM","2026-02-04",{"date":82,"type":83},"2026-02-05","ACTUAL",{"date":85,"type":83},"2021-10-01",{"date":87,"type":61},"2027-10",{"name":5,"class":6},1]